If you're long MNTA, you should be happy with the FDA's guidelines for interchangeable FoBs as specified in the draft. They read as though they were written by MNTA.
The requirement for a switching study seems reasonable, and I don't expect it to be changed in the FDA's final guidance document.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.